Polyfunctional T Cell and Neutralizing Antibody Responses to ACAM2000<sup>TM</sup> Smallpox Vaccine Immunization in Primary-Vaccinated Individuals
- 1 Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
- 2 Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
- 3 Center of Excellence for Flow Cytometry, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
- 4 Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Abstract
Smallpox eradication was successful via prophylactic administration of live attenuated vaccinia virus. As a result of the discontinuation of the smallpox immunization program, many individuals are now susceptible to smallpox virus infection should it be used as a biological weapon. Presently, only individuals at high risk for exposure are required to receive smallpox vaccine, such as laboratory personnel that handle variola/vaccinia virus. This study endeavored to investigate a one-year period of vaccinia virus-specific T cell responses using polychromatic flow cytometry and neutralizing (Nt) antibody responses using plaque reduction neutralization test (PRNT) in individuals receiving primary immunization (n = 5) with ACAM2000 <sup>TM</sup> smallpox vaccine. Functional and phenotypic profiles of vaccinia virus-specific T cell responses were characterized. Each single functional measurement {CD107a/b expression, production of interferon g (IFN- g ), macrophage inflammatory protein 1 b (MIP-1 b ), interleukin 2 (IL-2), and tumor necrosis factor a (TNF- a )} demonstrated that vaccinia virus-specific CD8 + T cells were functional at least one time point after vaccination ( p ≤ 0.05). However, vaccinia virus-specific CD4 + T cells were functional only for MIP-1 b production ( p ≤ 0.05). Vaccinia virus-specific CD8 + T cells induced in these individuals showed increased polyfunctionality in at least 2 phenotypes relative to pre-vaccination ( p ≤ 0.05). Although only three of five individuals (60%) showed positive Nt antibody (titer ≥ 20) at first month after vaccination, all five individuals (100%) demonstrated Nt antibody at 2 months, post-immunization. Interestingly, all vaccinees could retain the Nt antibody for 6 months after primary vaccination. In conclusion, ACAM2000<sup>TM</sup> smallpox vaccine induced both polyfunctional T cell-and Nt antibody-responses in primary immunized individuals.
- Puissant, B. and Combadière, B. (2006) Keeping the Memory of Smallpox Virus. Cellular and Molecular Life Sciences, 63, 2249-2259. http://dx.doi.org/10.1007/s00018-006-6313-2
- Monath, T.P., Caldwell, J.R., Mundt, W., Fusco, J., Johnson, C.S., Buller, M., et al. (2004) ACAM2000 Clonal Vero Cell Culture Vaccinia Virus (New York City Board of Health strain)—A Second-Generation Smallpox Vaccine for Biological Defense. International Journal of Infectious Diseases, 8S2, S31-S44.
- Kennedy, R.B., Ovsyannikova, I.G., Jacobson, R.M. and Poland, G.A. (2009) The Immunology of Smallpox Vaccine. Current Opinion in Immunology, 21, 314-320. http://dx.doi.org/10.1016/j.coi.2009.04.004
- Moss, B. (2011) Smallpox Vaccines: Targets of Protective Immunity. Immunological Reviews, 239, 8-16. http://dx.doi.org/10.1111/j.1600-065X.2010.00975.x
- Harrington, L.E., Most, R., Whitton, J.L. and Ahmed, R. (2002) Recombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope. Journal of Virology, 76, 3329-3337. http://dx.doi.org/10.1128/JVI.76.7.3329-3337.2002
- Taub, D.D., Ershler, W.B., Janowski, M., Artz, A., Keys, M.L., McKelveya, J., et al. (2008) Immunity from Smallpox Vaccine Persists for Decades: A Longitudinal Study. American Journal of Medicine, 121, 1058-1064. http://dx.doi.org/10.1016/j.amjmed.2008.08.019
- Precopio, M.L., Betts, M.R., Parrino, J., Price, D.A., Gostick, E., Ambrozak, D.R., et al. (2007) Immunization with Vaccinia Virus Induces Polyfunctional and Phenotypically Distinctive CD8+ T Cell Responses. Journal of Experimental Medicine, 204, 1405-1416. http://dx.doi.org/10.1084/jem.20062363
- Cox, J.H. (1999) HIV-1-Specific Cytotoxic T-Cell Assays. In: Michael, N.L. and Kim, J.H., Eds., Methods in Molecular Medicine, Vol. 17: HIV Protocols, Humana Press, Totowa, 355-371. http://dx.doi.org/10.1385/0-89603-369-4:355
- Newman, F.K., Frey, S.E., Blevins, T.P., Mandava, M., Bonifacio, A., Yan, L., et al. (2003) Improved Assay to Detect Neutralizing Antibody Following Vaccination with Diluted or Undiluted Vaccinia (Dryvax) Vaccine. Journal of Clinical Microbiology, 41, 3154-3157. http://dx.doi.org/10.1128/JCM.41.7.3154-3157.2003
- Fenner, F., Henderson, D.A., Arita, I., Jezek, Z. and Ladnyi, I.D. (1988) Smallpox and Its Eradication. World Health Organization, Geneva.
- Nalca, A. and Zumbrun, E.E. (2010) ACAM2000: The New Smallpox Vaccine for United States Strategic National Stockpile. Drug Design, Development and Therapy, 4, 71-79. http://dx.doi.org/10.2147/DDDT.S3687